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Summary
Background Atopic dermatitis (AD) is the most common inflammatory skin disease.
It is highly heterogeneous in clinical presentation, treatment response, disease
trajectory and associated atopic comorbidities. Immune biomarkers are dysregu-
lated in skin and peripheral blood.
Aims We used noninvasive skin and peripheral biomarkers to observe the effects
of real-world topical corticosteroid (TCS) treatment in infants with AD, by mea-
suring skin and blood biomarkers before and after therapy.
Methods Seventy-four treatment-na€ıve infants with AD underwent 6 weeks of TCS
treatment. Stratum corneum (SC) and plasma blood biomarkers as well as SC nat-
ural moisturizing factor (NMF) were measured before and after TCS therapy.
Immune markers included innate, T helper (Th)1 and Th2 immunity, angiogene-
sis, and vascular factors. AD severity was assessed by the Scoring Atopic Dermati-
tis index, and skin barrier function by transepidermal water loss (TEWL). Twenty
healthy infants were recruited as controls.
Results TCS therapy predictably led to improvement in disease severity. Levels of
immune markers in the skin and in the peripheral blood showed significant
change from baseline, though most did not reach healthy control levels. The
most prominent change from baseline in the SC was in markers of innate
immune activation, interleukin (IL)-18, IL-8 and IL-1a, and the Th2 chemokines
C-C motif chemokine (CCL)17 and CCL22. In blood, the largest changes were in
Th2-skewed biomarkers: CCL17, IL-13, CCL22, IL-5, and CCL26. TEWL
decreased after therapy; no significant changes from baseline were found for
NMF.
Conclusions The profound impact of topical therapy on systemic biomarkers sug-
gests that the skin compartment generates a major component of dysregulated
systemic cytokines in infant AD. There may be long-term beneficial effects of
correcting systemic immune dysregulation through topical therapy.
What is already known about this topic?
• Atopic dermatitis (AD) is a clinically heterogeneous condition with multiple clini-
cal manifestations and a complex pathogenesis.
• Noninvasive sampling of the stratum corneum has yielded significant insights into
cytokine profiles of this compartment in AD.
• Peripheral blood signatures have distinct cytokine profiles in childhood AD.
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What does this study add?
• We show the effects of topical corticosteroid (TCS) therapy on both skin-derived
and peripheral blood biomarkers.
• TCS therapy had an effect on the cutaneous compartment but also substantially
normalized the peripheral blood compartment cytokine signatures.
• The long-term effects of normalizing peripheral immune signatures are unknown
but could potentially be beneficial.
What is the translational message?
• TCS therapy can normalize systemic immune dysregulation in infant AD.
Atopic dermatitis (AD) is the most common chronic inflam-
matory skin disease and is associated with a significant burden
of disease and cost of treatment.1 AD is associated with multi-
ple atopic comorbidities including food allergy, asthma, aller-
gic rhinitis and eosinophilic oesophagitis in addition to
emerging evidence of additional comorbidities, including neu-
ropsychiatric and metabolic morbidity.2–4 As AD begins in
infancy, a better understanding of early-life mechanisms and
responses to first-line treatments is important.
To date, very few studies have examined skin and periph-
eral biomarkers in infants with AD. Recently, several studies
have demonstrated, using tape stripping and a variety of ana-
lytical methodologies, how noninvasive biomarkers derived
from the stratum corneum (SC) can give significant insights
into immune dysregulation at the skin surface and that these
biomarkers have a different profile from those of the periph-
eral blood component.5–10
While our previous work used multiplex immunoassays of
tape-strip eluates for cytokine analysis,10,11 and high-perfor-
mance liquid chromatography analyses for filaggrin break-
down products [natural moisturizing factor (NMF)],10,11
others have used approaches such as transcriptomic and pro-
teomic analysis in a variety of patient cohorts including adults
and children.7–9,12,13
Collectively, these studies serve to show the utility of these
noninvasive techniques and together, in a complementary fash-
ion, they have helped to establish a better understanding of local
immune signatures in the outer epidermis. Here, we aimed to
study the effects of 6 weeks of real-life topical corticosteroid
(TCS) therapy on treatment-na€ıve infants with respect to skin bar-
rier function, and SC- and peripheral blood-derived biomarkers.
Patients and methods
Study population
One hundred infants with AD were recruited, from Novem-
ber 2012 to November 2014, in a dedicated AD clinic in
Our Lady’s Children’s Hospital, Dublin. A single, experienced
paediatric dermatologist (M.A.McA.) assessed, recruited and
treated all infant patients. Patients had to be less than 12
months of age with moderate or severe AD, as determined
by a SCORing Atopic Dermatitis (SCORAD) score of 25 or
greater, for at least 6 weeks’ duration. Furthermore, patients
had to be treatment na€ıve, apart from the use of emollients
and 1% hydrocortisone cream or ointment. Twenty control
infants were recruited when attending Children’s Health Ire-
land at Crumlin, Dublin, for elective procedures under gen-
eral anaesthetic. Controls were recruited if they did not have
AD, any history suggestive of AD or atopy, or any other
inflammatory skin disease; and they were age- and ethnically
matched. All infants and children were examined to ensure
an absence of inflammatory skin disease. All parents and car-
ers were asked to refrain from application of any topical
agents for 24 h prior to assessment. The study was con-
ducted in accordance with the Declaration of Helsinki and
approved by the Research Ethics Committee of Children’s
Heath Ireland, Dublin. Written informed consent was
obtained from all patients’ parents.
Clinical assessment
Patients met the Hanifin and Rajka criteria for diagnosis of
AD.14 Age of onset of AD was recorded. Severity was assessed
using the SCORAD index.15 All patients had moderate or sev-
ere AD defined by a SCORAD of 25 or greater. Objective
SCORAD (oSCORAD), the component of SCORAD without the
subjective scores of parental assessment of sleep loss and itch,
was also recorded. A summary of clinical and demographic
characteristics of our recruited patients is tabulated in Table 1.
Therapy
As this was an observational study, patients were treated with
TCS in line with normal clinical practice, and treatment course
was tailored to the child’s disease severity according to
© 2020 The Authors. British Journal of Dermatology
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department practice. A summary of steroid potencies and used
volume is listed in Table S1 (see Supporting Information).
Stratum corneum transepidermal water loss
measurement
Transepidermal water loss (TEWL) measurements were done
under standardized conditions (room temperature of 22–
25 °C and humidity levels of 30–35%). Patients were acclima-
tized for a minimum of 10 min, with their volar forearm skin
exposed. Measurements were taken from an area of clinically
unaffected skin on the volar forearm using the Tewameter
TM 300 (Courage + Khazaka electronic GmbH, Cologne, Ger-
many).
Sampling of the stratum corneum by tape stripping
The SC was sampled using the previously described method,10
using circular adhesive tape strips (38 cm2, D’Squame, Mona-
derm, Monaco) and a D-Squame D500 pressure instrument
(CuDerm, Dallas, TX, USA). Eight consecutive tape strips were
sampled, all from the same site, in nonlesional skin, 2 cm
away from visible eczematous areas, and immediately stored
at –80 °C.
Blood sampling
Plasma was separated by centrifugation, pipetted into cry-
otubes, and stored frozen at –80 °C until analysis.
Determination of filaggrin breakdown products (natural
moisturizing factor) in the stratum corneum
Analysis of NMF breakdown components (histidine, pyrroli-
done carboxylic acid, trans-urocanic acid and cis-urocanic acid)
was performed on the fourth consecutive strip according to
the method previously described.10,16
Filaggrin genotyping
All patients were screened for the nine most common filaggrin
gene (FLG) mutations found in the Irish population (R501X,
Y2092X, 2282del4, R2447X, S3247X, R3419X, 3702X,
S1040X and G1139X), as previously described.10
Cytokine analysis in tape strips and plasma samples
Cytokine concentrations in the SC and plasma were measured using
MESO QuickPlex SQ 120 (Meso Scale Diagnostics, LLC, Rockville,
MA, USA) according to the manufacturer’s instructions, apart from
the samples being undiluted, and in the case of SC samples incuba-
tion time was prolonged to 16 h. Cytokines were measured on pre-
configured multiplex panels as follows: proinflammatory panel:
interleukin (IL)-1b, IL-2 and IL-13 in the SC, with additionally
interferon gamma, IL-4, IL-6, IL-10, IL12p70 and tumour necrosis
factor (TNF)-a in plasma; chemokine panel: C-C motif chemokine
(CCL)2, CCL3, CCL4, CCL13, CCL17, CCL22, IL-8 and C-X-C motif
chemokine 10 in the SC, with additionally CCL5 and CCL11 in
plasma; cytokine panel: granulocyte-macrophage colony-stimulat-
ing factor, IL-1a, IL-5, IL-7, IL-12p40, IL-15, IL-16 and IL-17A in
the SC, with additionally TNF-b, IL-17A and vascular endothelial
growth factor (VEGF) in plasma; vascular panel: C-reactive protein
(CRP), serum amyloid A (SAA), soluble intercellular adhesion
molecule (sICAM-1) and soluble vascular cell adhesion molecule 1
(sVCAM-1) in both SC and plasma; and angiogenesis panel: vascular
endothelial growth factor receptor 1 (VGFR1, or Flt-1), angiopoi-
etin-1 receptor, VEGF-A and VEGF-C in the SC, with additionally
basic fibroblast growth factor, placental growth factor and VEGF-D
in plasma. Some singleplex assays were also carried out (IL-18).
For statistical analysis, cytokine concentrations below the
detection limit (but above the bottom of the bottom of the curve
fit) were taken unchanged. Samples with cytokine concentrations
that were below the fit curve range (the signal was below the bot-
tom of the bottom of the curve fit, no concentration given) were
assigned half the value of the lowest sample concentration below
Table 1 Demographic and clinical data





Age (months), median (range) 74 (08–118) 70 (0–123)
Age at onset (months), median (range) 18 (05–101) –
T0 T6
SCORAD, median (range) 450 (234–913) 164 (0–796) –






SCORAD, SCORing Atopic Dermatitis; TEWL, transepidermal water loss; FLG, filaggrin gene.
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the detection limit to maintain the ranking order. The limits of
detection and number of samples with concentrations below the
fit curve range are given in Table S2 (see Supporting Information)
for each cytokine measured in SC and plasma.
Extraction of immune biomarkers from the stratum
corneum
The fifth consecutive tape strip was used to measure biomar-
ker levels in the SC. To determine the amount of soluble pro-
tein and biomarkers, 06 mL of phosphate-buffered saline
(Merck KGaA, Darmstadt, Germany) with 0005% Tween-20
(Sigma-Aldrich, St Louis, MO, USA) was added to each vial,
and the vials were left on ice for 30 min. Extraction was per-
formed with an ultrasound sonifier equipped with a probe
(Salm en Kipp, Breukelen, the Netherlands) for 15 min in ice
water. The extract was centrifuged (2 min at 15 000 g), and
supernatant aliquots of 60 µL were frozen at –80 °C until fur-
ther analysis. As the amount of SC on the tape strips varies,
the concentration of biomarkers in the SC was normalized for
protein content, which was determined using the Pierce Micro
BCA protein assay kit (Thermo Fisher Scientific, Waltham,
MA, USA), with bovine serum albumin supplied as standard.
Statistical analysis
All calculations were performed using GraphPad Prism 7
(GraphPad Software, San Diego, CA, USA). The data on
immune biomarkers were log transformed before statistical
testing. Differences in biomarker levels between baseline val-
ues and after 6 weeks of therapy were determined by the Wil-
coxon matched-pairs signed-rank test. Differences in
biomarker levels between healthy controls and post-therapy
values in infants with AD were tested by a two-tailed Mann–
Whitney U-test. P-values were corrected for multiple testing
using a Benjamini–Hochberg procedure.
Results
Study patients
We initially recruited 100 infants with moderate or severe AD
and 20 healthy control infants.10 From this cohort, 74 patients
returned for examination after 6 weeks of topical therapy.
Immune biomarkers were analysed in the plasma of 47 patient
samples and 20 control samples. SC samples were analysed for
NMF in 74 patient samples and 18 controls, and for immune
biomarkers in 66 patient samples and 13 controls. All raw
study data are listed in Table S3 (see Supporting Information).
Disease severity and barrier function
Most children showed significant improvement in disease
severity as assessed either by SCORAD or oSCORAD (Figure 1a,
b). Only two children showed an increase in SCORAD and
three an increase in oSCORAD. Recovery of the skin barrier
(a) (b) (c) (d)
Figure 1 (a, b) Severity of disease as assessed by (a) SCORing Atopic Dermatitis (SCORAD) and (b) objective SCORAD (oSCORAD), in infants
with AD at baseline (ADT0) and after 6 weeks of topical corticosteroid therapy (ADT6). (c, d) Skin barrier function as assessed by (c)
transepidermal water loss (TEWL) and (d) stratum corneum (SC) natural moisturizing factor (NMF) levels in patients at ADT0 and at ADT6,
compared with healthy controls (Ctrl). Differences in disease severity, TEWL and NMF levels at ADT0 and ADT6 were determined by two-tailed
Wilcoxon matched-pairs signed-rank test. Benjamini–Hochberg corrected P-values: ****P < 00001, ***P < 0001.
Figure 2 Levels of immune biomarkers in the stratum corneum (SC) and plasma of infants with atopic dermatitis (AD) at baseline (ADT0) and
after 6 weeks of topical corticosteroid therapy (ADT6) vs. healthy controls (Ctrl). SC: n (AD) = 66 and n (Ctrl) = 13; plasma: n (AD) = 47 and n
(Ctrl) = 20. Values are log transformed and shown as box-and-whisker plots. Differences in biomarker levels between ADT0 and ADT6 were
determined by two-tailed paired t-test or Wilcoxon matched-pairs signed-rank test. Differences in biomarker levels between healthy controls and
infants with AD at ADT6 were determined by two-tailed Mann–Whitney U-test (raw data in Table S3; see Supporting Information). CRP, C-reactive
protein; CCL, C-C motif chemokine; Flt-1, vascular endothelial growth factor receptor 1; GM-CSF, granulocyte-macrophage colony-stimulating
factor; IL, interleukin; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule;
VEGF, vascular endothelial growth factor. Benjamini–Hochberg corrected P-values: ****P < 00001, ***P < 0001, **P < 001, *P < 005.
© 2020 The Authors. British Journal of Dermatology
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was observed, albeit to a lesser extent than the improvement
measured by SCORAD: median TEWL values decreased from
215 g m–2 h–1 at baseline to 148 g m–2 h–1 after therapy
(Figure 1c). Of 71 children with TEWL value measured, 18
showed reduction in skin barrier function from baseline. Med-
ian TEWL values in infants with AD were significantly higher
than the median in healthy infants (110 g m–2 h–1). After 6
weeks of therapy, the majority of children (59 of 73) still had
higher TEWL values as compared with healthy controls. To
explore whether carriers of FLG mutations have a different
therapy response, changes in disease severity and TEWL were
tested in subgroups with respect to FLG mutations. As shown
in Table S4 (see Supporting Information), both subgroups
showed similar changes from baseline in SCORAD/oSCORAD
and TEWL.
Natural moisturizing factor
NMF values at baseline and after therapy are shown in Fig-
ure 1d. In contrast with disease severity and barrier function,
Figure 3 Fold differences between levels of immune biomarkers in the stratum corneum (SC) and plasma of infants with atopic dermatitis (AD)
at baseline and after 6 weeks of topical corticosteroid therapy. Data are presented only for biomarkers showing significant change from baseline.
Results are expressed as mean  SEM. SC: n (AD) = 66 and n (Ctrl) = 13; plasma: n (AD) = 47 and n (Ctrl) = 20. Fold difference was calculated
by dividing the individual post-therapy biomarker level in the SC and plasma of each patient by the corresponding baseline value. CRP, C-reactive
protein; CCL, C-C motif chemokine; Flt-1, vascular endothelial growth factor receptor 1; GM-CSF, granulocyte-macrophage colony-stimulating
factor; IL, interleukin; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule;
Th2, T helper type 2; VEGF, vascular endothelial growth factor. ****P < 00001, ***P < 0001, **P < 001, *P < 005.
© 2020 The Authors. British Journal of Dermatology
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no improvement in NMF was achieved after therapy, irrespec-
tive of the presence of FLG mutations (Table S4 and Figure S1;
see Supporting Information).
Stratum corneum biomarkers
Of 27 measured biomarkers in the SC, 22 showed significantly
different levels at baseline and after 6 weeks of therapy
(Table S3). Median levels of immune markers in patients at
baseline and after therapy that showed significant difference
from baseline either in the SC or plasma, along with levels in
healthy participants, are shown in Figure 2. Although the
majority of cytokines showed changes toward values found in
healthy participants, their levels still did not reach those of
healthy participants (Table S3). Differences between baseline
and post-therapy levels were further elaborated for biomarkers
that showed significant change from baseline, and expressed
as fold difference (Figure 3). The most prominent change in
the SC was found for markers of innate immune activation
(IL-18 and IL-8), and angiogenesis and vascular markers
(Flt-1 and VEGF-A) (decrease from baseline).
Systemic biomarkers
Of 40 measured biomarkers in plasma, 10 showed signifi-
cantly different levels at baseline and after 6 weeks of therapy
(Table S3). Median levels of immune markers in patients at
baseline and after therapy that showed significant difference
from baseline either in SC or plasma, along with levels in
healthy participants, are shown in Figure 2. In plasma, the lar-
gest changes were found for T-helper (Th)2-skewed biomark-
ers (CCL17, IL-13, CCL22, IL-5 and CCL26), and vascular cell
adhesion markers sICAM-1 and sVCAM-1, which all decreased
after therapy.
While some biomarkers showed a directional change (i.e. a
parallel increase or decrease after therapy) between the SC and
plasma, some showed discordance between the two, or were
significantly different from baseline only in the SC or plasma
(Figures 2 and 3). For example, CCL17, CCL22, slCAM1,
sVCAM-1, and Flt-1 changed in the same direction (a
decrease) after therapy in both SC and plasma. However, sev-
eral inflammatory biomarkers after therapy were significantly
different from baseline only in the SC; these included cytoki-
nes IL-18, IL-1a, IL-2, IL-15, IL-16, IL-12p40, chemokines
IL-8, CCL2, CCL3 and CCL4, along with vascular and angio-
genesis factors VEGF-A, CRP and SAA. In contrast, IL-13
decreased only in plasma (Figures 2 and 3; Table S3). In gen-
eral, levels of all cytokines showed large variability between
patients, in both SC and plasma and on all timepoints. As an
illustration, Figure 4 shows the individual data on cytokines
for representatives of innate immune activation (IL-18), Th2
(CCL17) and angiogenesis (Flt-1).
Correlations between baseline levels of biomarkers and
changes in disease severity (SCORAD and oSCORAD) and
epidermal barrier function (transepidermal water loss)
To investigate whether baseline improvement in disease severity
is associated with the baseline levels of immune markers and
NMF, a Spearman’s rank correlation analysis was performed.
The results are presented as a heat map (Figure 5a). In general,
very few immune markers show a significant association
between baseline value and changes in either SCORAD or
oSCORAD (DSCORAD and DoSCORAD, respectively). Further-
more, the type of markers that were significantly correlated dif-
fers between plasma and SC. Among SC markers, a significant
association was found for the chemokines IL-8 and CCL17, and
for the angiogenesis and vascular factors Flt-1, SAA, sICAM-1
Figure 4 Individual levels of selected immune markers in infants with atopic dermatitis (AD) measured in the stratum corneum (SC) and plasma,
at baseline (ADT0) and after 6 weeks of topical corticosteroid therapy (ADT6) vs. healthy controls (Ctrl): interleukin (IL)-18 (innate immunity), C-
C motif chemokine (CCL)17 (T helper 2 cell cytokine) and vascular endothelial growth factor receptor 1 (Flt-1) (angiogenesis factor). Differences
in IL-18, CCL17 and Flt-1 levels between baseline and post-therapy values were determined by two-tailed paired t-test or two-tailed Wilcoxon
matched-pairs signed-rank test. Benjamini–Hochberg corrected P-values: ****P < 00001, **P < 001, *P < 005.
© 2020 The Authors. British Journal of Dermatology
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and sVCAM-1. For plasma markers, the strongest association
was observed for TNF-a, followed by VEGF-A and CCL22.
Next, we investigated whether changes in biomarker levels
paralleled changes in disease severity. As seen from the heat
map showing Spearman correlation coefficients and corre-
sponding significance levels (Figure 5b), more immune mark-
ers showed a significant association with either SCORAD or
oSCORAD, in particular those measured in the SC (VEGF-A,
Flt-1, IL-8, IL-18, IL-1b, sICAM-1, CCL17 and CCL22). In
plasma, significant correlations were found only between the
changes in oSCORAD and TNF-a and CCL22.
In general, the correlations were stronger with oSCORAD as
compared with SCORAD. Baseline levels of NMF were not cor-
related with either changes in SCORAD (or oSCORAD) or their
changes from baseline (DSCORAD and DoSCORAD). Severity
at baseline as assessed by oSCORAD and SCORAD is highly
correlated with disease severity after TCS therapy and changes
in these severity scores from baseline (D values). The strongest
association with baseline values was found for decrease in
severity, DSCORAD (r = –050; P < 0001) and DoSCORAD (r
= –055; P < 0001).
Discussion
Noninvasive testing of stratum corneum structural components
and cytokines offers significant insights into the biological
activity of AD in nonlesional skin.11,17,18 We have previously
demonstrated the utility of tape stripping as a methodological
(a) (b)
Figure 5 Spearman’s correlation coefficients (a) comparing baseline stratum corneum tape-strip (TS) and plasma biomarker values with changes in
disease severity [change in SCORing Atopic Dermatitis (DSCORAD) and objective SCORAD (DoSCORAD)]; and (b) comparing changes in
biomarker values at baseline with corresponding changes in disease severity (DSCORAD and DoSCORAD). bFGF, basic fibroblast growth factor;
CCL, C-C motif chemokine; CRP, C-reactive protein; CXCL, C-X-C motif chemokine; Flt-1, vascular endothelial growth factor receptor 1; GM-CSF,
granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; NMF, natural moisturizing factor; PIGF, placental growth
factor; SAA, serum amyloid A; sICAM, soluble intercellular adhesion molecule; sVCAM, soluble vascular cell adhesion molecule; TEWL,
transepidermal water loss; Th2, T helper type 2; Tie-2, angiopoietin-1 receptor; TNF, tumour necrosis factor; VEGF, vascular endothelial growth
factor. Benjamini–Hochberg corrected P-values: ***P < 0001, **P < 001, *P < 005.
© 2020 The Authors. British Journal of Dermatology
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approach to characterize the immunological signature of the
SC in infantile AD.10 Here we extend our work to show the
effects of 6 weeks of TCS therapy on both the structural pro-
teins of the SC, through filaggrin-derived NMF, and cytokine
profiles in the SC and the peripheral blood plasma.19 TCS ther-
apy led to significant changes from baseline in the levels of
immune markers; however, for some biomarkers the magni-
tude and direction of the changes differed between skin and
peripheral blood. Both SC and blood showed a decrease in
levels of Th2 chemokines and angiogenesis factors, while the
changes in markers of innate immunity were found only in
the SC. Interestingly, changes in levels of IL-13, a key cytokine
in the pathophysiology of AD,20 were found only in blood.
There are very few studies in children in which cytokines
were measured in the SC by tape strips, at the protein
level.6,10,11 The results in these studies show a consistent pat-
tern of cytokine levels in the SC; the most pronounced differ-
ences between healthy and AD skin were found for the
cytokines of innate immunity (decrease in IL-1a and increase
in IL-1b and IL-8 in AD) and for Th2 chemokines CCL17 and
CCL22 (increased in AD). In contrast to these immune mark-
ers, less conclusive findings were reported for IL-13.6,10,11
Recently, He et al.21 performed proteomic profiling of a
large number of markers of the skin barrier and immune
response in nonlesional and lesional skin of adult patients with
AD before and after systemic dupilimab therapy. Concordant
with the present study, a significant decrease in CCL17 was
found, while IL-13 was not listed among the cytokines that
were changed either in lesional or nonlesional skin. In contrast
to the protein levels found in tape-strip samples, increased
levels of IL-13 protein as well as mRNA have been found in
skin biopsies,22 suggesting that local translation into protein
in the skin is not the cause of the aberrant pattern of IL-13 in
tape-strip samples. Highly increased IL-13 has also been
reported in most of the transcriptomic studies performed in
tape stripping of nonlesional and lesional skin.23,17 Clearly, as
previously stated by Lyubchenko et al.,6 IL-13 in tape-strip
samples measured as a protein seems not to be a suitable mar-
ker in AD. Difference in biological half-life, protein binding,
transport from epidermis to the SC, or sensitivity of analytical
determination may explain this.
Nevertheless, in the present study, several other Th2 cytoki-
nes such as CCL2, CCL17 and CCL22, and furthermore cytoki-
nes of innate immunity, angiogenesis and vascular factors, did
show differences between healthy and AD skin at base-
line,6,10,11 and before and after TCS therapy, making tape
stripping a useful technique for profiling biomarkers of a
broad signature.
However, before implementation in research and clinical
practice, there are several methodological issues that should
be evaluated and validated. In tape-strip studies, SC samples
are collected from different SC depths (i.e. a different tape
number, which only approximates exact SC depth). We
showed previously that NMF gradually increases with SC
depth, reaching a plateau at around the sixth tape. In the
present study we used tape number four, before maximal
NMF levels are reached.24,25 Nonetheless, in our previous
studies we showed a good correlation in NMF levels col-
lected at different depths.26 This has also been observed for
various cytokines, which showed a strong correlation
between the fifth and eighth tapes.26 This is consistent with
good concordance in proteomic data of cytokines obtained
from the fifth tape (the present study) and from the 17th
and 19th tapes in the study by Lyubchenko et al.6
Another possible source of variation is the distance from
lesions at which nonlesional skin is sampled. In our recent
study aimed at evaluation of spatial and biological variability
of cytokines and NMF in tape stripping, we showed that the
effect of spatial distance is biomarker specific but that levels of
the majority of cytokines show a decrease with increasing dis-
tance, while IL-1a and NMF show an opposite pattern.26 This
emphasizes the need for thorough evaluation regarding SC
depth and distance from lesion by study design.
We made three key observations. Firstly, TCS therapies
have a profound impact on the SC cytokine profile, with
marked normalization across multiple cytokines including
those associated with innate immunity, type-2 immunity and
vascular cell adhesion and angiogenesis. Given the pluripo-
tency of corticosteroids, this is not a surprising finding. Sec-
ondly, we did not detect a difference in NMF, a good proxy
of filaggrin expression, after 6 weeks of therapy, showing that
expression of this key structural protein is unaffected by the
anti-inflammatory effects of TCSs, and NMF deficiency
remains following 6 weeks of treatment.27 For patients who
have experienced good control of their AD following TCS
treatment, this observation implies they have a residual epi-
dermal barrier deficit and susceptibility to future flares, as is
seen clinically.2
Our third observation is the most novel and striking: we
show that 6 weeks of TCS treatment has a marked effect on
the peripheral blood inflammatory cytokine profile. Two
potential mechanisms could explain this observation. The
first, and we suggest the most likely, is that the aberrant
peripheral blood signature in infant AD is largely derived
from the skin compartment. This is in agreement with a
recent study by Pavel et al.,22 who showed a significant corre-
lation between mRNA and protein expression of various
cytokines, indicating local translation into protein in the skin
and pinpointing the skin as the primary source for the
upregulated proteins. A second potential but less likely expla-
nation is that TCSs are sufficiently absorbed to have a sys-
temic effect on immune profiles. Elucidation of the relative
importance of these potential mechanisms is beyond the
scope of this observational paper. However, the implications
are potentially very important.
The association of atopic comorbidities in childhood AD is
well understood on an observational level, historically termed
the ‘atopic march’,3 and has some shared genetic basis,28 but
the mechanisms underlying these disease associations are
poorly understood. It is plausible that leakage of Th2 cytokines
from the skin into the peripheral circulation causes an expan-
sion of the type 2 response, and primes other epithelial tissues
© 2020 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2021)
TCS therapy and inflammatory markers in infant AD, M. A. McAleer et al. 9
such as respiratory, nasal, gastrointestinal and oesophageal
epithelia to develop type 2 inflammation when provoked with
additional challenges such as a viral respiratory infection.29–31
It is possible that aggressive treatment of skin inflammation
in early childhood AD could control or reduce peripheral Th2
immune skewing and reduce exposure of other epithelia to a
Th2-skewed environment. The hypothesis that early and
aggressive treatment of AD could lower the risk of subsequent
atopic comorbidities could be tested in well designed, ade-
quately powered longitudinal randomized controlled clinical
trials. Some observational cohorts, where early and aggressive
treatment appears to reduce the risk of concomitant food
allergy,32 lend support to conduct of such studies.
To conclude, we demonstrate again the potential for mini-
mally invasive skin tape stripping to disclose significant patho-
physiological insights. We also show the systemic and local
effects of short-term TCS use and the potential for topical
therapy in young children to profoundly influence their sys-
temic immune profile.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Table S1 Topical corticosteroid therapy during the 6-week
treatment period.
Table S2 Cytokine/chemokine limits of detection and num-
ber of cytokines with concentrations below fit curve range in
the stratum corneum and in plasma.
Table S3 Cytokine and chemokine levels (log-transformed
values) and differences between their levels in the stratum
corneum and plasma of healthy control children and children
with atopic dermatitis (AD) at baseline, and in children with
AD between baseline and after 6 weeks of therapy.
Table S4 Severity of disease, skin barrier function and stra-
tum corneum natural moisturizing factor levels at baseline and
after 6 weeks of topical corticosteroid therapy stratified for
filaggrin genotype.
Figure S1 Stratum corneum natural moisturizing factor
levels at baseline and after 6 weeks of topical corticosteroid
therapy.
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